Canine Primary Hyperaldosteronism: Diagnosis and Management

Primary hyperaldosteronism in dogs is an endocrine disorder characterized by excessive aldosterone secretion from the adrenal cortex, typically due to an aldosterone-producing adenoma or carcinoma. This condition leads to systemic hypertension and hypokalemia, requiring prompt diagnosis and targeted management to prevent progressive cardiovascular and renal damage. This article provides veterinarians with an evidence-based framework for recognizing clinical signs, confirming the diagnosis through appropriate testing, and implementing surgical or medical treatment strategies.

At a Glance

Pathophysiology and Etiology

Primary hyperaldosteronism results from autonomous aldosterone secretion by the adrenal cortex, independent of the renin-angiotensin system. The most common causes are unilateral aldosterone-producing adenoma (aldosteronoma) or carcinoma, though bilateral adrenal hyperplasia has been reported. Aldosterone acts on the distal renal tubules to increase sodium reabsorption and potassium excretion, leading to volume expansion, hypertension, and hypokalemia. Chronic hypokalemia can cause renal tubular dysfunction, polyuria, polydipsia, and generalized muscle weakness. The condition is distinct from secondary hyperaldosteronism, where renin secretion is elevated due to renal disease or other stimuli.

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide updated recommendations for diagnosing and managing adrenal disorders, including hyperaldosteronism. These guidelines emphasize the importance of systematic evaluation and evidence-based treatment approaches. The Merck Veterinary Manual offers comprehensive information on adrenal gland function and disorders in dogs, serving as a foundational reference for understanding the pathophysiology.

Clinical Presentation and Signalment

Dogs with primary hyperaldosteronism typically present with signs related to hypertension and hypokalemia. Common owner-reported concerns include polyuria, polydipsia, lethargy, exercise intolerance, and episodic weakness. Some dogs may exhibit cervical ventroflexion or other signs of neuromuscular dysfunction due to hypokalemia. Ocular findings such as retinal detachment or hemorrhage may occur secondary to severe hypertension.

The condition is most frequently diagnosed in middle-aged to older dogs, with no strong breed predilection. However, certain breeds may be overrepresented in case reports. A thorough history should include questions about thirst, urination frequency, appetite, activity level, and any observed weakness or collapse episodes. Physical examination should include careful fundic examination, cardiac auscultation for murmurs or arrhythmias, and palpation of the abdomen for adrenal masses.

Diagnostic Approach

Initial Laboratory Evaluation

The diagnostic workup begins with a complete blood count, serum biochemistry panel, and urinalysis. Serum electrolyte measurement is critical, as hypokalemia is a hallmark finding. However, normokalemia does not exclude the diagnosis, particularly in early or mild cases. Serum sodium may be normal or mildly elevated. Azotemia may be present if hypertension has caused renal injury or if hypokalemia has induced renal tubular dysfunction.

Blood pressure measurement should be performed using a standardized protocol, ideally with Doppler or oscillometric methods. Hypertension is defined as systolic blood pressure consistently above 160 mmHg, though values exceeding 180 mmHg are common in hyperaldosteronism. Multiple measurements over several visits may be necessary to confirm persistent hypertension.

Hormonal Testing

Confirmation of primary hyperaldosteronism requires demonstration of elevated aldosterone concentration with suppressed renin activity. The aldosterone:renin ratio (ARR) is the preferred screening test. Blood samples should be collected under standardized conditions, ideally in the morning after an overnight fast, with the dog in a calm state. Medications that affect the renin-angiotensin-aldosterone system, such as spironolactone, angiotensin-converting enzyme inhibitors, and diuretics, should be withheld for an appropriate washout period before testing.

A high ARR indicates primary hyperaldosteronism, while a low or normal ratio suggests secondary causes. Reference intervals vary between laboratories, so results should be interpreted using the specific laboratory's established cutoffs. In cases where the ARR is equivocal, a saline suppression test or fludrocortisone suppression test may be considered, though these are less commonly performed in clinical practice.

Adrenal Imaging

Adrenal imaging is essential for identifying the underlying adrenal lesion and guiding surgical planning. Abdominal ultrasound is the most accessible modality and can detect adrenal masses as small as 5 to 10 mm. An adrenal adenoma typically appears as a well-defined, hypoechoic nodule within the adrenal gland, while carcinomas may be larger, irregular, and invasive. Ultrasound also allows assessment of the contralateral adrenal gland, liver, and regional lymph nodes for evidence of metastasis.

Computed tomography (CT) or magnetic resonance imaging (MRI) provides superior anatomic detail and is recommended when surgical intervention is planned. These modalities better characterize tumor extent, vascular invasion, and involvement of adjacent structures. CT angiography can evaluate the adrenal vasculature, which is important for surgical planning. The 1997 Veterinary Clinics of North America publication on imaging of adrenal gland disorders provides foundational information on the utility of these techniques.

Differential Diagnoses

Primary hyperaldosteronism must be distinguished from secondary hyperaldosteronism, which occurs in response to renal disease, heart failure, or other conditions that activate the renin-angiotensin system. Other causes of hypertension in dogs include chronic kidney disease, diabetes mellitus, hyperadrenocorticism, and pheochromocytoma. Hypokalemia may also result from renal tubular acidosis, gastrointestinal losses, or diuretic therapy. A systematic diagnostic approach using the ARR and adrenal imaging helps differentiate these conditions.

Medical Management

Aldosterone Antagonists

Spironolactone is the cornerstone of medical therapy for primary hyperaldosteronism. As a competitive aldosterone receptor antagonist, it blocks the effects of excess aldosterone at the distal renal tubule, promoting sodium excretion and potassium retention. This helps control both hypertension and hypokalemia. Spironolactone is typically administered twice daily with food to enhance absorption and reduce gastrointestinal side effects.

Monitoring should include serum electrolytes, blood pressure, and renal function at regular intervals. Hyperkalemia can occur, particularly in dogs with concurrent renal impairment or those receiving other potassium-sparing medications. Dose adjustments may be necessary based on individual response and tolerance.

Antihypertensive Therapy

Amlodipine, a calcium channel blocker, is frequently used as a first-line antihypertensive agent in dogs with hyperaldosteronism. It causes vasodilation and reduces systemic vascular resistance, effectively lowering blood pressure. Amlodipine is typically administered once daily and can be combined with spironolactone for additive effects.

Blood pressure should be monitored closely after initiating or adjusting antihypertensive therapy. The goal is to achieve systolic blood pressure below 160 mmHg while avoiding hypotension. Gradual dose titration is recommended to prevent rapid blood pressure drops that could compromise organ perfusion.

Electrolyte Management

Hypokalemia should be corrected using potassium supplementation, typically in the form of potassium gluconate or potassium citrate. Oral supplementation is preferred, and the dose should be adjusted based on serial serum potassium measurements. In severe hypokalemia with clinical signs such as muscle weakness or cardiac arrhythmias, intravenous potassium supplementation may be necessary under careful monitoring.

Once spironolactone therapy is established, potassium supplementation may be reduced or discontinued, as the medication itself promotes potassium retention. Regular electrolyte monitoring is essential to avoid iatrogenic hyperkalemia.

Monitoring and Follow-Up

Dogs receiving medical management require lifelong monitoring. A typical schedule includes recheck examinations every 1 to 3 months initially, then every 3 to 6 months once stable. Each visit should include blood pressure measurement, serum electrolyte panel, and renal function testing. Adrenal imaging may be repeated annually or if clinical signs change to assess tumor progression.

Owners should be educated about signs of hypertension (e.g., sudden blindness, seizures, lethargy) and hypokalemia (e.g., weakness, collapse, cervical ventroflexion) that warrant immediate veterinary attention. A written action plan for emergency situations is recommended.

Surgical Management

Preoperative Preparation

Unilateral adrenalectomy is the treatment of choice for aldosterone-producing adenoma or carcinoma without evidence of metastasis. Preoperative stabilization is critical to reduce surgical risk. Hypertension should be controlled with amlodipine and spironolactone, and hypokalemia should be corrected before anesthesia. A thorough preoperative evaluation includes complete blood count, serum biochemistry, urinalysis, coagulation profile, and thoracic imaging to rule out metastatic disease.

Electrocardiography is recommended to assess for arrhythmias related to hypokalemia or hypertension. Echocardiography may be indicated in dogs with suspected cardiac disease or severe hypertension. The 2025 Veterinary Anaesthesia and Analgesia publication on management of refractory hypotension during adrenalectomy highlights the importance of careful anesthetic planning and intraoperative monitoring.

Surgical Technique

Adrenalectomy is performed through a ventral midline celiotomy or a flank approach, depending on tumor location and surgeon preference. The affected adrenal gland is carefully dissected from surrounding structures, with attention to the adrenal vasculature. The adrenal vein must be ligated and transected. For right-sided tumors, the short adrenal vein entering the caudal vena cava requires careful dissection. For left-sided tumors, the adrenal vein drains into the left renal vein.

Intraoperative complications include hemorrhage, hypotension, and arrhythmias. Hypotension may occur due to blood loss, anesthetic effects, or sudden changes in vascular tone after tumor removal. The 2025 publication on refractory hypotension during adrenalectomy in a dog treated with phenoxybenzamine provides insights into managing this complication. Close communication between the surgeon and anesthesiologist is essential throughout the procedure.

Postoperative Care

After adrenalectomy, dogs require intensive monitoring for 24 to 48 hours. Blood pressure, heart rate, respiratory rate, and urine output should be recorded frequently. Serum electrolytes and renal function should be assessed daily. Hypertension typically resolves within days to weeks after successful tumor removal, but antihypertensive medications may need to be tapered gradually.

Hypotension can occur postoperatively, particularly if the contralateral adrenal gland is suppressed or if there is residual anesthetic effect. Intravenous fluid therapy should be carefully managed to avoid volume overload. Pain management using multimodal analgesia is important for recovery.

Prognosis After Surgery

The prognosis for dogs with aldosterone-producing adenoma is generally good after complete surgical excision. Most dogs experience resolution of hypertension and hypokalemia, and long-term survival is expected. For dogs with adrenal carcinoma, the prognosis depends on tumor stage and completeness of excision. Carcinomas may recur locally or metastasize to the liver, lungs, or regional lymph nodes.

Postoperative monitoring should include periodic blood pressure measurement, serum electrolyte panels, and adrenal imaging to detect recurrence. The 1985 Journal of the American Veterinary Medical Association publication on idiopathic hyperaldosteronism in a dog provides historical context for understanding the natural history of this condition.

Common Failure Patterns

Diagnostic Delays

Primary hyperaldosteronism is often underdiagnosed because hypertension and hypokalemia are not consistently evaluated in dogs with nonspecific signs. Failure to measure blood pressure in dogs with polyuria, polydipsia, or weakness can delay diagnosis. Similarly, hypokalemia may be attributed to other causes without considering adrenal disease. Routine blood pressure measurement and serum electrolyte assessment in at-risk populations can improve detection rates.

Incomplete Medical Control

Some dogs do not achieve adequate blood pressure or electrolyte control with standard medical therapy. This may result from insufficient dosing, poor owner compliance, or progressive tumor growth. Inadequate monitoring can allow hypertension or hypokalemia to persist, leading to target organ damage. Regular recheck examinations and dose adjustments are necessary to optimize outcomes.

Surgical Complications

Adrenalectomy carries inherent risks, including hemorrhage, hypotension, and damage to adjacent structures. Inexperienced surgeons or inadequate preoperative preparation increase complication rates. Referral to a veterinary surgical specialist is recommended for complex cases. The 2025 publication on refractory hypotension during adrenalectomy underscores the need for advanced anesthetic management.

Tumor Recurrence

Incomplete excision of adrenal carcinoma can lead to local recurrence or metastasis. Even with complete excision, some carcinomas have aggressive biologic behavior. Long-term monitoring is essential to detect recurrence early. Owners should be informed about the possibility of recurrence and the importance of follow-up care.

Limitations and Considerations

Diagnostic Limitations

The aldosterone:renin ratio is influenced by many factors, including medications, stress, and sample handling. False positives and false negatives can occur. Reference intervals vary between laboratories, and there is no universally accepted cutoff. Suppression tests may be necessary in equivocal cases but are not widely validated in dogs.

Adrenal imaging has limitations. Small adenomas may not be visible on ultrasound, and CT or MRI may be required for detection. Differentiating adenoma from carcinoma based on imaging alone is not always possible, histopathology is the gold standard. Bilateral disease may be missed if only one adrenal gland is examined.

Treatment Limitations

Spironolactone can cause gastrointestinal side effects, including anorexia and vomiting. Hyperkalemia is a risk, particularly in dogs with renal impairment. The medication may also have antiandrogenic effects, though these are less clinically relevant in dogs.

Amlodipine is generally well tolerated but can cause reflex tachycardia or peripheral edema in some dogs. Blood pressure must be monitored to avoid hypotension, especially when combining multiple antihypertensive agents.

Surgery is not feasible for all dogs. Contraindications include metastatic disease, poor anesthetic risk, bilateral adrenal involvement, and owner financial constraints. In these cases, lifelong medical management is the only option.

Prognostic Uncertainty

The long-term prognosis for dogs with adrenal carcinoma is variable. Some dogs survive for years after surgery, while others experience rapid disease progression. There are no reliable biomarkers to predict individual outcomes. Owners should be counseled about the range of possible outcomes and the need for ongoing monitoring.

Welfare and Safety Context

Primary hyperaldosteronism significantly impacts canine welfare through the effects of hypertension and hypokalemia. Untreated hypertension can cause target organ damage, including retinopathy, nephropathy, and cerebrovascular events. Severe hypokalemia can lead to muscle weakness, cardiac arrhythmias, and respiratory compromise. Prompt diagnosis and effective management are essential to maintain quality of life.

The World Organisation for Animal Health (WOAH) provides international standards for animal health and welfare, including guidelines for the management of endocrine diseases. Veterinarians should adhere to these standards when treating dogs with hyperaldosteronism. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines offer evidence-based recommendations for clinical practice.

Safety considerations include the use of medications with potential side effects and the risks associated with anesthesia and surgery. Informed consent should be obtained from owners after discussing the benefits, risks, and alternatives of each treatment option. Written discharge instructions should include medication administration, monitoring parameters, and emergency contact information.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internal medicine specialist or surgical specialist in the following situations:

• Diagnostic uncertainty after initial testing
• Severe or refractory hypertension despite medical therapy
• Recurrent or severe hypokalemia
• Large or invasive adrenal masses on imaging
• Suspected bilateral adrenal disease
• Poor anesthetic risk or complex surgical cases
• Lack of response to standard medical management
• Owner request for second opinion or advanced care

Referral centers can offer advanced diagnostic testing, including CT or MRI, and specialized surgical expertise. Collaboration with a boarded internist or surgeon can optimize outcomes for complex cases.

Practical Decision Framework for Managing Canine Primary Hyperaldosteronism

Treatment Selection Algorithm Based on Clinical Staging

A structured decision framework helps veterinarians navigate the complex choices between surgical and medical management of primary hyperaldosteronism. This framework integrates diagnostic findings, patient factors, and owner considerations to guide treatment selection. The algorithm begins with confirmation of the diagnosis through aldosterone:renin ratio testing and adrenal imaging, as outlined in the 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines.

Stage 1: Unilateral Adenoma Without Metastasis

For dogs with a solitary adrenal adenoma confirmed on CT or MRI and no evidence of metastasis on thoracic imaging or abdominal ultrasound, unilateral adrenalectomy is the recommended first-line treatment. The decision to proceed with surgery requires assessment of anesthetic risk, including cardiac evaluation with echocardiography if hypertension has been prolonged or severe. Dogs with systolic blood pressure consistently above 180 mmHg should receive preoperative stabilization with amlodipine and spironolactone for 2 to 4 weeks before surgery. Serum potassium should be above 3.5 mmol/L before anesthesia induction. The 2025 Veterinary Anaesthesia and Analgesia publication on management of refractory hypotension during adrenalectomy emphasizes the importance of preoperative blood pressure control to reduce intraoperative complications.

Stage 2: Unilateral Carcinoma Without Metastasis

Adrenal carcinoma requires more urgent surgical intervention due to the potential for rapid growth and metastasis. Preoperative staging should include CT of the abdomen and thorax to evaluate for vascular invasion, lymph node involvement, and pulmonary metastases. If the carcinoma is resectable and no distant metastases are identified, adrenalectomy with wide margins is indicated. The surgical approach may require en bloc resection of adjacent tissues if invasion is present. Owners should be counseled that even with complete excision, the risk of recurrence is higher than with adenoma. The 1997 Veterinary Clinics of North America publication on imaging of adrenal gland disorders provides guidance on distinguishing adenoma from carcinoma based on imaging characteristics, though histopathology remains the gold standard.

Stage 3: Bilateral Adrenal Disease

Bilateral adrenal hyperplasia or bilateral adenomas present a treatment challenge. Unilateral adrenalectomy is not appropriate because the remaining adrenal gland will continue to produce excess aldosterone. Medical management with spironolactone and amlodipine is the mainstay of therapy. In rare cases of bilateral adenomas where one gland is significantly larger, partial adrenalectomy of the dominant gland may be considered, but this approach carries high risk and should only be performed by experienced surgeons. The 1985 Journal of the American Veterinary Medical Association publication on idiopathic hyperaldosteronism in a dog describes the historical recognition of bilateral disease and its management challenges.

Stage 4: Metastatic or Unresectable Disease

When adrenal carcinoma has metastasized to the liver, lungs, or regional lymph nodes, or when the primary tumor is invasive and unresectable, surgical cure is not possible. Medical management focuses on controlling hypertension and hypokalemia to maintain quality of life. Spironolactone is used at the highest tolerated dose, typically 2 to 4 mg/kg twice daily, with amlodipine added for blood pressure control. Potassium supplementation may be necessary initially but should be tapered as spironolactone takes effect. Palliative debulking surgery may be considered in select cases to reduce tumor burden and improve medical control, but this decision requires specialist consultation.

Stage 5: Poor Surgical Candidate or Owner Declines Surgery

Dogs with significant comorbidities such as chronic kidney disease, heart failure, or uncontrolled diabetes may not be suitable for adrenalectomy. Similarly, owners may decline surgery due to financial constraints or concerns about anesthetic risk. In these cases, lifelong medical management is the appropriate approach. The treatment goals are to maintain systolic blood pressure below 160 mmHg, serum potassium above 3.5 mmol/L, and prevent target organ damage. Regular monitoring every 1 to 3 months is essential to adjust medications and detect complications early.

Record System for Longitudinal Monitoring

A standardized record system improves consistency in monitoring and facilitates early detection of treatment failure or disease progression. The following record template can be adapted for clinical use.

Initial Diagnostic Record

Follow-Up Visit Record

Medication Adjustment Log

Surgical Case Record

Troubleshooting Method for Common Clinical Challenges

Challenge 1: Persistent Hypertension Despite Maximal Medical Therapy

When systolic blood pressure remains above 160 mmHg despite spironolactone at 4 mg/kg twice daily and amlodipine at 0.2 to 0.4 mg/kg once daily, the following troubleshooting steps should be followed.

First, verify blood pressure measurement technique. Use a standardized protocol with the dog in a quiet environment, allow 5 to 10 minutes for acclimation, and take 5 to 7 consecutive readings discarding the first and last. Cuff size should be approximately 40% of limb circumference. If measurements are consistent, proceed to evaluate medication compliance. Ask owners about missed doses, timing of administration, and whether medications are given with food. Spironolactone absorption is enhanced with food, but some dogs may vomit or refuse food containing medication.

Second, assess for concurrent conditions that may contribute to hypertension. Chronic kidney disease, hyperadrenocorticism, diabetes mellitus, and pheochromocytoma can all cause or exacerbate hypertension. Perform a complete blood count, serum biochemistry panel, urinalysis with culture, and thyroid profile. If hyperadrenocorticism is suspected, perform an ACTH stimulation test or low-dose dexamethasone suppression test. The Merck Veterinary Manual provides guidance on differentiating these conditions.

Third, consider adding a second antihypertensive agent. If spironolactone and amlodipine are insufficient, an angiotensin-converting enzyme inhibitor such as enalapril at 0.5 mg/kg twice daily may be added. However, efficacy may be limited in primary hyperaldosteronism because aldosterone secretion is autonomous and not renin-dependent. Beta-blockers such as atenolol at 0.5 to 1 mg/kg twice daily can be used for heart rate control if reflex tachycardia is present. Specialist consultation is recommended before adding third-line agents.

Fourth, repeat adrenal imaging to assess for tumor progression. An enlarging tumor may produce more aldosterone, requiring higher medication doses. If the tumor has become invasive or metastatic, surgical options should be reconsidered if not previously pursued.

Challenge 2: Refractory Hypokalemia

When serum potassium remains below 3.5 mmol/L despite spironolactone therapy and oral potassium supplementation, the following approach is indicated.

First, verify spironolactone dose and administration. The dose should be at least 2 mg/kg twice daily, and some dogs require up to 4 mg/kg twice daily. Ensure the medication is given with food to maximize absorption. If gastrointestinal side effects such as vomiting or anorexia occur, consider dividing the dose into three daily administrations or switching to a different formulation.

Second, assess potassium supplementation. Oral potassium gluconate at 2 to 4 mEq per 10 kg body weight twice daily is typical. If the dog is not receiving supplementation, initiate therapy. If already receiving supplementation, consider increasing the dose by 25% to 50% and rechecking potassium in 3 to 5 days. Monitor for hyperkalemia, especially if renal function is impaired.

Third, evaluate for concurrent potassium-wasting conditions. Renal tubular acidosis, gastrointestinal disease causing vomiting or diarrhea, and diuretic therapy can all contribute to hypokalemia. Perform urinalysis with pH measurement, fecal examination, and review all medications the dog is receiving. Discontinue any unnecessary medications that may promote potassium loss.

Fourth, consider intravenous potassium supplementation if hypokalemia is severe (below 3.0 mmol/L) and associated with clinical signs such as muscle weakness, cervical ventroflexion, or cardiac arrhythmias. Intravenous potassium should be administered at a rate not exceeding 0.5 mEq/kg/hour with continuous ECG monitoring. Once stabilized, transition to oral therapy.

Challenge 3: Postoperative Hypotension After Adrenalectomy

Hypotension during or after adrenalectomy requires prompt recognition and management. The 2025 Veterinary Anaesthesia and Analgesia publication on refractory hypotension during adrenalectomy in a dog treated with phenoxybenzamine provides important insights into this complication.

First, assess for hypovolemia. Intraoperative blood loss should be estimated, and fluid resuscitation initiated with crystalloids at 10 to 20 mL/kg boluses. If hypotension persists, consider colloids such as hetastarch at 5 to 10 mL/kg or blood products if anemia is present. Central venous pressure monitoring can guide fluid therapy.

Second, evaluate for residual anesthetic effects. Inhalant anesthetics cause vasodilation and myocardial depression. Reducing the vaporizer setting or switching to a total intravenous anesthetic protocol may improve blood pressure. The anesthesiologist should be consulted for protocol adjustments.

Third, consider the possibility of relative adrenal insufficiency. After removal of an aldosterone-producing tumor, the contralateral adrenal gland may be suppressed and unable to mount an adequate stress response. Administer a stress dose of hydrocortisone at 0.5 to 1 mg/kg intravenously and assess response. If blood pressure improves, continue glucocorticoid supplementation and taper over 24 to 48 hours.

Fourth, if hypotension is refractory to fluid therapy and glucocorticoids, vasopressor support may be necessary. Dopamine at 5 to 10 mcg/kg/minute or norepinephrine at 0.05 to 0.3 mcg/kg/minute can be used with continuous blood pressure monitoring. The goal is to maintain mean arterial pressure above 60 mmHg. Specialist consultation is recommended for complex cases.

Challenge 4: Suspected Tumor Recurrence After Surgery

When a dog that previously underwent adrenalectomy develops recurrent hypertension, hypokalemia, or both, tumor recurrence should be suspected. The following steps are recommended.

First, confirm the diagnosis with repeat aldosterone and renin measurement. A high aldosterone:renin ratio indicates recurrent hyperaldosteronism. If the ratio is normal, investigate other causes of hypertension and hypokalemia.

Second, perform adrenal imaging with CT or MRI to evaluate the surgical site and the contralateral adrenal gland. Local recurrence appears as a soft tissue mass at the previous surgical site. The contralateral gland should be assessed for new tumor development. Thoracic imaging is indicated to evaluate for metastasis.

Third, if recurrence is confirmed, determine whether the tumor is resectable. If the recurrence is localized and there is no evidence of metastasis, repeat adrenalectomy may be considered. However, surgical dissection is more challenging due to scar tissue, and the risk of complications is higher. Referral to a surgical specialist is strongly recommended.

Fourth, if repeat surgery is not feasible or declined, initiate or reinstitute medical management with spironolactone and amlodipine. The same monitoring schedule as for primary medical management should be followed. Owners should be counseled about the likelihood of progressive disease and the need for ongoing care.

Common Failure Patterns in Clinical Management

Failure Pattern 1: Inadequate Preoperative Stabilization

Rushing to surgery without achieving adequate blood pressure and electrolyte control increases the risk of intraoperative and postoperative complications. Dogs with systolic blood pressure above 180 mmHg are at higher risk for hemorrhage and hypotension during adrenal manipulation. Hypokalemia increases the risk of cardiac arrhythmias during anesthesia. A minimum of 2 to 4 weeks of medical stabilization is recommended before elective adrenalectomy. If emergency surgery is necessary due to tumor rupture or other acute indications, the surgical team should be prepared for increased complication rates.

Failure Pattern 2: Incomplete Diagnostic Workup

Skipping thoracic imaging or comprehensive abdominal imaging before surgery can lead to unexpected findings during the procedure. Metastatic disease may be present but not detected on physical examination or basic ultrasound. CT provides superior sensitivity for detecting small pulmonary metastases and vascular invasion. The 1997 Veterinary Clinics of North America publication emphasizes the importance of complete preoperative imaging for surgical planning.

Failure Pattern 3: Inadequate Owner Education

Owners who do not understand the importance of medication compliance, regular monitoring, and recognition of emergency signs are more likely to experience poor outcomes. Written discharge instructions should include a medication schedule, monitoring parameters, and emergency contact information. A follow-up phone call 24 to 48 hours after discharge can reinforce instructions and address questions. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines recommend providing owners with a written action plan for managing complications.

Failure Pattern 4: Insufficient Monitoring Frequency

Infrequent recheck examinations allow hypertension and hypokalemia to persist undetected, leading to target organ damage. Dogs on medical therapy should be rechecked every 1 to 3 months initially, then every 3 to 6 months once stable. Blood pressure should be measured at every visit, and serum electrolytes should be assessed at least every 3 months. Annual adrenal imaging is recommended to monitor for tumor progression.

Failure Pattern 5: Delayed Referral

Veterinarians who attempt to manage complex cases without specialist input may miss diagnostic or therapeutic opportunities. Referral should be considered early in the diagnostic process, particularly when imaging findings are equivocal, when medical therapy is not achieving goals, or when surgical intervention is planned. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide specific criteria for specialist referral.

Welfare and Safety Context for Decision Making

The welfare implications of primary hyperaldosteronism extend beyond the direct effects of hypertension and hypokalemia. Dogs with uncontrolled disease experience reduced quality of life due to lethargy, weakness, and polyuria. Chronic hypertension can cause progressive renal damage, retinal detachment, and cerebrovascular events. Severe hypokalemia can lead to life-threatening cardiac arrhythmias and respiratory muscle weakness.

The World Organisation for Animal Health (WOAH) provides international standards for animal health and welfare that emphasize the importance of timely diagnosis and effective treatment. Veterinarians have an ethical obligation to offer the best available care based on current evidence. When surgical cure is possible, it should be presented as the preferred option. When surgery is not feasible, medical management should be optimized to maintain quality of life.

Safety considerations include the risks associated with spironolactone therapy, including hyperkalemia and gastrointestinal side effects. Amlodipine can cause reflex tachycardia and peripheral edema. Surgical risks include hemorrhage, hypotension, and damage to adjacent structures. Owners should be informed of these risks during the consent process, and written documentation should be maintained in the medical record.

Professional Escalation Criteria

Veterinarians should seek specialist consultation or referral in the following situations:

• Diagnostic uncertainty after initial aldosterone:renin ratio and imaging
• Systolic blood pressure above 180 mmHg despite maximal medical therapy
• Serum potassium below 3.0 mmol/L despite spironolactone and supplementation
• Adrenal mass larger than 3 cm or with invasive characteristics on imaging
• Suspected bilateral adrenal disease
• Poor anesthetic risk due to concurrent cardiac, renal, or hepatic disease
• Intraoperative complications such as refractory hypotension
• Suspected tumor recurrence after adrenalectomy
• Owner request for second opinion or advanced care options

Referral to a board-certified veterinary internal medicine specialist or surgical specialist can provide access to advanced diagnostic testing, including CT angiography and adrenal vein sampling, as well as specialized surgical expertise. The American College of Veterinary Internal Medicine (ACVIM) and American College of Veterinary Surgeons (ACVS) maintain directories of board-certified specialists for referral purposes.

Frequently Asked Questions

What are the most common clinical signs of primary hyperaldosteronism in dogs?

The most common signs are polyuria, polydipsia, lethargy, exercise intolerance, and episodic muscle weakness. Some dogs present with cervical ventroflexion or collapse due to severe hypokalemia. Ocular signs such as retinal detachment or hemorrhage may occur secondary to hypertension. Owners may also report increased thirst and urination.

How is primary hyperaldosteronism diagnosed in dogs?

Diagnosis involves demonstrating elevated aldosterone concentration with suppressed renin activity, typically using the aldosterone:renin ratio. Adrenal imaging with ultrasound, CT, or MRI is used to identify the underlying adrenal lesion. Blood pressure measurement and serum electrolyte assessment are essential components of the diagnostic workup.

What is the treatment of choice for primary hyperaldosteronism?

Unilateral adrenalectomy is the treatment of choice for aldosterone-producing adenoma or carcinoma without metastasis. Medical management with spironolactone and amlodipine is used when surgery is not feasible or while awaiting surgery. Lifelong monitoring is required regardless of treatment modality.

Can primary hyperaldosteronism be managed medically without surgery?

Yes, medical management with spironolactone and amlodipine can effectively control hypertension and hypokalemia in many dogs. However, this approach does not address the underlying adrenal tumor, and progressive tumor growth may occur. Lifelong medication and regular monitoring are necessary.

What is the prognosis for dogs with primary hyperaldosteronism?

The prognosis is generally good for dogs with aldosterone-producing adenoma after complete surgical excision. For dogs with adrenal carcinoma, the prognosis depends on tumor stage and completeness of excision. Dogs managed medically can have good quality of life with appropriate treatment and monitoring.

Are there any breed predispositions for primary hyperaldosteronism?

No strong breed predilection has been established, though certain breeds may be overrepresented in case reports. The condition is most frequently diagnosed in middle-aged to older dogs. Any dog with hypertension and hypokalemia should be evaluated for primary hyperaldosteronism regardless of breed.

What medications should be avoided in dogs with primary hyperaldosteronism?

Potassium-sparing diuretics other than spironolactone should be used with caution due to the risk of hyperkalemia. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be less effective in primary hyperaldosteronism because aldosterone secretion is autonomous. These medications should be used only under specialist guidance.

How often should dogs with primary hyperaldosteronism be monitored?

Dogs should be rechecked every 1 to 3 months initially after diagnosis or treatment changes, then every 3 to 6 months once stable. Each visit should include blood pressure measurement, serum electrolyte panel, and renal function testing. Adrenal imaging may be repeated annually or if clinical signs change.

Related Veterinary Guides

• Dog
• Canine Hyperadrenocorticism Cushings Diagnostic Management
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines.. Journal of the American Animal Hospital Association, 2023.
• Feline adrenal disorders.. Clinical techniques in small animal practice, 2007.
• Idiopathic hyperaldosteronism in a dog.. Journal of the American Veterinary Medical Association, 1985.
• Endocrine diseases in animals.. Hormone research, 2009.
• Control of sodium reabsorption.. British medical journal, 1969.
• Imaging of adrenal gland disorders.. The Veterinary clinics of North America. Small animal practice, 1997.
• Trilostane in Dogs. Veterinary Clinics of North America Small Animal Practice, 2010.
• Management of refractory hypotension during adrenalectomy in a dog treated with phenoxybenzamine. Veterinary Anaesthesia and Analgesia, 2025.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.